Maxim raised the firm’s price target on Mesoblast (MESO) to $30 from $18 and keeps a Buy rating on the shares after the FDA approved Ryoncil as the first mesenchymal stromal cell, therapy in the United States.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO: